Assetmark Inc. Sells 2,772 Shares of Lantheus Holdings, Inc. $LNTH

Assetmark Inc. decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.7% during the second quarter, Holdings Channel.com reports. The fund owned 98,659 shares of the medical equipment provider’s stock after selling 2,772 shares during the quarter. Assetmark Inc.’s holdings in Lantheus were worth $8,076,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State of Michigan Retirement System raised its stake in Lantheus by 0.6% during the 1st quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider’s stock worth $1,620,000 after acquiring an additional 100 shares during the period. Signaturefd LLC raised its position in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 116 shares during the last quarter. Intrust Bank NA raised its position in shares of Lantheus by 2.9% during the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock valued at $431,000 after buying an additional 125 shares during the last quarter. Focus Financial Network Inc. raised its position in shares of Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock valued at $293,000 after buying an additional 136 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider’s stock valued at $653,000 after buying an additional 139 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 4.0%

LNTH stock opened at $57.69 on Monday. The firm has a fifty day moving average price of $54.14 and a 200 day moving average price of $69.87. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The firm has a market cap of $3.92 billion, a PE ratio of 15.34 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $92.51 million during the quarter. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the topic of several recent analyst reports. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a “hold” rating in a research report on Monday, August 11th. TD Cowen reduced their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. JMP Securities reduced their price objective on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. Mizuho reduced their price objective on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Finally, William Blair reiterated a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Hold” and an average target price of $74.50.

Insiders Place Their Bets

In other Lantheus news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 1.50% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.